Under his leadership, Mundipharma was able to post 26 straight quarters of growth.
Mundipharma Global Chief Executive Officer, Raman Singh, has clinched the Executive of the Year for Pharmaceuticals at the SBR Management Excellence Awards 2018. It is his second straight year to be recognised with the prestigious title.
Mr Singh oversees Mundipharma’s operations in the US, Canada, Europe, Latin America, the Middle East and Africa, and Asia Pacific. Under his leadership, Mundipharma has expanded from three therapy areas to a wide variety of covering pharmaceuticals, over-the-counter medicines and fast moving consumer products. Specialist areas include, analgesia, biosimilars, oncology, oncology supportive care, ophthalmology, respiratory care and consumer healthcare.
He is the driving force behind the organization achieving 40% YoY growth and 26 consecutive quarters of growth. With him at the helm, Mundipharma has expanded its market reach to over 120 countries.
Mundipharma’s outstanding growth and expansion is driven by its mission to improve the quality of patient care in Singapore and emerging markets around the world. Since Mr Singh joined Mundipharma in 2011, the company has become the fastest growing pharmaceutical firm in emerging markets. The organisation has also grown its profile as a healthcare industry thought leader, with Mr Singh frequently interviewed by leading international media and included in global summits such as the World Economic Forum.
In addition, Mundipharma has completed more than 40 deals under Mr Singh’s leadership via commercial partnerships. This includes the company expanding its oncology portfolio in the Middle East, Africa, Latin America, and Asia Pacific as well as guiding the expansion of the firm’s ophthalmology portfolio in the Middle East and Africa. He also spearheads innovation in Mundipharma’s regional headquarters in Singapore.
Mr Singh's success at Mundipharma has not gone unnoticed. Aside from being recognised as Executive of the Year for Pharmaceuticals, Mr Singh and Mundipharma have also garnered accolades such as CEO of the Year 2018 by Influential Brands, Top 100 Global CEOs 2018 by CEO Magazine, 3rd Most Powerful Person in Healthcare 2018 by Medicine Maker with the firm placing in the top ten for the last four years, as well as Best Company in an emerging market at the Scrip Awards 2016 and Best CEO at the Pharmaceutical Industry Asia by Business Worldwide Magazine CEO Awards in 2017. Under his guidance, Mundipharma has also been recognised as a top employer in many of the countries it operates in.
The Singapore Business Review Management Excellence Awards was held on November 22, 2018 at the Conrad Centennial Singapore. The award honours the country's most outstanding business leaders, including trailblazing individuals and teams whose initiatives have brought tangible business gains for their company's operations.
The 2018 nominees were judged by a panel consisting of Henry Tan, Managing Director at NEXIA TS; David Chew, Executive Director, Risk Advisory Deloitte Southeast Asia, Lim Wei Wei, Partner, Practice Leader, Governance, and Risk at Baker Tilly TFW; Pardeep Singh Khosa, Director of Dispute Resolution at Drew & Napier; and Yang Eu Jin, Partner and Co Head of Capital Markets Practice at RHTLaw Taylor Wessing LLP.
If you would like to join the 2019 awards and be awarded as one of the most outstanding management executives of Singapore, please email email@example.com.
Do you know more about this story? Contact us anonymously through this link.